Scholarlink

Background <p>Pseudobulbar affect (PBA) is a disabling neuropsychiatric condition characterized by sudden, involuntary episodes of crying or laughing incongruent with mood. It occurs in several neurological disorders, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, and traumatic brain injury (TBI). Dextromethorphan/quinidine (DM/Q) is the only Food and Drug Administration (FDA)-approved therapy for PBA, but optimal dosing and safety profiles remain uncertain.</p> Objective <p>To evaluate the efficacy and safety of different DM/Q dosing regimens for treating PBA through a systematic review and network meta-analysis.</p> Methods <p>A comprehensive search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov was conducted through March 2025. Randomized controlled trials reporting outcomes on the Center for Neurologic Study–Lability Scale (CNS-LS), Visual Analog Scale–Quality of Life (VAS-QOL), Visual Analog Scale–Quality of Recovery (VAS-QOR), and adverse events were included. Analyses were performed using R (netmeta package), and bias was assessed with the Cochrane RoB 2.0 tool.</p> Results <p>Five randomized controlled trials comprising 605 participants were analyzed. DM/Q 20/10&#xa0;mg and 30/10&#xa0;mg significantly improved CNS-LS scores (mean difference [MD] − 2.52 and − 2.45, respectively), while DM/Q 30/30&#xa0;mg produced greater gains in VAS-QOL (MD 17.20) and VAS-QOR (MD 14.90). Dizziness was the only statistically significant, dose-related adverse event.</p> Conclusion <p>DM/Q combination therapy provides effective symptom control for PBA, with favorable tolerability. Both 20/10&#xa0;mg and 30/10&#xa0;mg doses improve emotional lability, while 30/30&#xa0;mg yields additional quality-of-life benefits. Further studies should assess long-term safety and disorder-specific dosing optimization.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of dextromethorphan/quinidine in treating pseudobulbar affect in neurological disorders: A systematic review and dose-classified network meta-analysis

  • 期刊论文

  • 发表日期：

    2026年1月14日

查看全文
  • Muneeb Ahmad Muneer,
  • Irra Tariq,
  • Eeshal Zulfiqar,
  • Shaila Sharmin Saaki,
  • Ishita Gupta,
  • Syed Muhammad Nasir Abbas Bokhari,
  • Amogh Verma,
  • Rachana Mehta,
  • Ranjana Sah,
  • Syed Ijlal Ahmed

摘要

Background

Pseudobulbar affect (PBA) is a disabling neuropsychiatric condition characterized by sudden, involuntary episodes of crying or laughing incongruent with mood. It occurs in several neurological disorders, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, and traumatic brain injury (TBI). Dextromethorphan/quinidine (DM/Q) is the only Food and Drug Administration (FDA)-approved therapy for PBA, but optimal dosing and safety profiles remain uncertain.

Objective

To evaluate the efficacy and safety of different DM/Q dosing regimens for treating PBA through a systematic review and network meta-analysis.

Methods

A comprehensive search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov was conducted through March 2025. Randomized controlled trials reporting outcomes on the Center for Neurologic Study–Lability Scale (CNS-LS), Visual Analog Scale–Quality of Life (VAS-QOL), Visual Analog Scale–Quality of Recovery (VAS-QOR), and adverse events were included. Analyses were performed using R (netmeta package), and bias was assessed with the Cochrane RoB 2.0 tool.

Results

Five randomized controlled trials comprising 605 participants were analyzed. DM/Q 20/10 mg and 30/10 mg significantly improved CNS-LS scores (mean difference [MD] − 2.52 and − 2.45, respectively), while DM/Q 30/30 mg produced greater gains in VAS-QOL (MD 17.20) and VAS-QOR (MD 14.90). Dizziness was the only statistically significant, dose-related adverse event.

Conclusion

DM/Q combination therapy provides effective symptom control for PBA, with favorable tolerability. Both 20/10 mg and 30/10 mg doses improve emotional lability, while 30/30 mg yields additional quality-of-life benefits. Further studies should assess long-term safety and disorder-specific dosing optimization.